Internal Server Error

Cyteir - About the company

Cyteir is a public company based in Cambridge (United States), founded in 2012. It operates as a Develops small molecules for the treatment of cancer and autoimmune diseases. Cyteir has raised $155M in funding from investors like Venrock, Celgene and RA Capital Management. The company has 3796 active competitors, including 1294 funded and 877 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Alnylam.

Company Details

Develops small molecules for the treatment of cancer and autoimmune diseases. The company's product pipeline includes CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters and CYT-0851 a combination with capecitabine and gemcitabine for patients with advanced ovarian cancer.
Website
cyteir.com
Social
X
Key Metrics
Founded Year
2012
Location
Cambridge, United States
Stage
Public
Total Funding
$155M in 7 rounds
Latest Funding Round
Investors
Ranked
Employee Count
1 as on Sep 30, 2026
Similar Companies
Exit Details
Public

Cyteir's IPO details

Cyteir got listed on Jun 18, 2021.
Click here to take a look at Cyteir's IPO in detail
Sign up to download Cyteir's company profile

Cyteir's funding and investors

Cyteir has raised a total funding of $155M over 7 rounds. Its first funding round was on Jul 15, 2014. Its latest funding round was a Post IPO round on Jun 22, 2021 for $*****. 1 investor participated in its latest round. Cyteir has 18 institutional investors.

Here is the list of recent funding rounds of Cyteir:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jun 22, 2021
5368595
Post IPO
8934797
6576311
5208617
4361503
Feb 11, 2021
7228972
Series C
2724220
8461181
9654773
Oct 14, 2019
4089403
Series B
6084463
6585610
lockAccess funding benchmarks and valuations. Sign up today!

Cyteir's founders and board of directors

Founder? Claim Profile

Cyteir's employee count trend

Cyteir has 1 employees as of Sep 26. Here is Cyteir's employee count trend over the years:
Employee count trend for Cyteir
lockUncover Cyteir's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Cyteir's Competitors and alternates

Top competitors of Cyteir include Jazz Pharmaceuticals, BeiGene and Alnylam. Here is the list of Top 10 competitors of Cyteir, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Jazz Pharmaceuticals
Jazz Pharmaceuticals
2003, Dublin (Ireland), Public
Developer of novel biopharmaceutical medicines for unmet medical needs
$265M
81/100
2nd
Logo for BeiGene
BeiGene
2010, Cambridge (United States), Public
Developer of targeted and immune-oncology drugs against cancer
$172M
81/100
3rd
Logo for Alnylam
Alnylam
2002, Cambridge (United States), Public
Developer of RNA interference-based therapeutics for multiple disorders
$17M
79/100
4th
Logo for Sana Biotechnology
Sana Biotechnology
2018, Seattle (United States), Public
Developer of engineered cell therapies for treating various human diseases
$821M
74/100
5th
Logo for Spark Therapeutics
Spark Therapeutics
2013, Philadelphia (United States), Acquired
Developer of gene therapy for rare diseases
$82.8M
73/100
6th
Logo for Ideaya Biosciences
Ideaya Biosciences
2015, San Francisco (United States), Public
Developer of oncology-focused precision medicine using molecular diagnostics
$157M
73/100
7th
Logo for Senti Bio
Senti Bio
2016, San Francisco (United States), Public
Developer of cell and gene therapies for patients living with incurable diseases
$158M
72/100
8th
Developer of antibody-based therapeutics for cancer therapy
$175M
72/100
9th
Logo for Syndax
Syndax
2005, Waltham (United States), Public
Developer of targeted therapies for the treatment of cancer
$198M
72/100
10th
Logo for Immuneel
Immuneel
2018, Bengaluru (India), Series B
Developer of T-cell therapies for the treatment of cancer
$49.8M
72/100
898th
Logo for Cyteir
Cyteir
2012, Cambridge (United States), Public
Develops small molecules for the treatment of cancer and autoimmune diseases
$155M
46/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Cyteir's competitors? Click here to see the top ones

Cyteir's Investments and acquisitions

Cyteir has made no investments or acquisitions yet.

Reports related to Cyteir

Here is the latest report on Cyteir's sector:

News related to Cyteir

lockFilter this list
•
Cyteir Therapeutics Insider Bought Shares Worth $503,238Stock Screener•Mar 25, 2024•Cyteir
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Cyteir

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford